Abstract:Objective To comprehensively evaluate the clinical efficacy of balloon dilation Eustachian tuboplasty (BET) combined with tympanic tube insertion (TTI) for the treatment of chronic recurrent secretory otitis media. Methods Articles about the treatment of chronic recurrent secretory otitis media by BET were searched in Wanfang data, CNKI, VIP, CBM, PubMed, Web of science and Cochrane library from database establishment to March 2020. All the relevant literatures were screened in strict accordance with the inclusion and exclusion criteria, and the extracted literatures were evaluated according to the Cochrane Literature Quality Evaluation Table. Meta-analysis was conducted on the outcome assessment indexes including the effective rate, the Eustachian Tube Dysfunction Questionaire (ETDQ-7) score, air-bone gap, average hearing threshold, acoustic immitance, otoendoscopy, incidence rate of adverse reaction and so on using Revman 5.3 software. Results Fourteen randomized controlled trials (RCT) with 710 patients (790 ears) were extracted, including 351 patients (395 ears) in the experimental group and 359 patients (395 ears) in the control group. The patients in the experimental group received BET combined with TTI, while those in the control group were treated by simple TTI. Meta-analysis results showed that the total effective rates at different time points (3, 6 and 12 months after treatment) in the experimental group were higher than those in the control group(all P<0.000 01). The ETDQ-7 values at different time points in experimental group were lower than those in the control group, and the differences were statistically significant (all P<0.000 01). The difference of air-bone gap at 12 months after treatment between the experimental group and the control group was statistically significant (P<0.05) while those at one and 6 months were insignificant. The improvements in the average hearing threshold, tympanometry, endoscopic signs of the experimental group were better than those of the control group (all P<0.05). The incidence rate of adverse reactions in the experimental group was lower than that in the control group with statistically significant difference (P<0.05). Conclusion Compared with TTI alone, BET combined with TTI can significantly improve the therapeutic effect of chronic recurrent secretory otitis media and reduce adverse reactions.